Analysis of Cronic

Granulomatous
Disease
Group Five :
Ario Wicaksono
Faza Anindhita
Fenty Dian Aryanti
Hot Nauli Simamora
Wisnu Widya Asmara

TWO GROUPS KAPLAN MEIER

The data set

Survival Probability by the Group of Treatment

When the patients of CG disease were given Gamma Interferon treatment, the
survival probability is :

Survival Probability by the Group of Treatment (2)

When the patients of CG disease were given Placebo treatment, the survival
probability is :

Two Groups Kaplan Meier Curve

Interpretation

From the picture beside, we can see that the treatment curve using
placebo consistently lower than the control curve using gamma
interferon after approximately in the day to 200 and above. This
indicates that treatment using gamma interferon is better to overcome
serious infection than the treatment using placebo.

LOG RANK TEST

Hypothesis
Ho: There are no differences in survival between
patients who use an Gamma Interferon and patients
who use a Placebo.
Hi:
There are differences in survival between
patients who use an Gamma Interferon and patients
who use a Placebo.
Reject Ho if the p-value < = 0.10 (10%)

Log Rank Test

Decision:
Because of p-value = 0.0854 < 0.10 then we reject Ho
Conclusions:
Based on the Log Rank test output results for this study can be
concluded that there was significant differences in survival
between patients who use an Gamma Interferon and patients
who use a Placebo.

COX PROPORTIONAL HAZARD

Cox PH Model
Full Model:

Z1 : Treatment code, 1 = gamma interferon (treatment) , 2 =

placebo (control group)
Z2 : Pattern of inheritance, 1 = X-linked , 2 = autosomal recessive
Z3 : Age, in years
Z4 : Height, in cm
Z5 : Weight, in kg
Z6 : Using corticosteroids at time of study entry, 1 = yes, 2 = no
Z7 : Using prophylactic antibiotics at time of study entry, 1 = yes,
2 = no.
Z8 : Sex, 1 = male, 2 = female
Z9 : Hospital category, 1 = US NIH (US - National Institutes of

Cox PH Model
Best Model:

Z1 : Treatment code, 1 = gamma interferon (treatment) , 2 = placebo

(control group)
Z4 : Height, in cm
Z5 : Weight, in kg
Z9 : Hospital category, 1 = US NIH (US - National Institutes of
Health), 2 = US - other, 3 = Europe-Amsterdam, 4 = Europe-other

Cox PH Test For The Best Model

Hypothesis
:

Interpretation
Based
on that output, p-value from all the variables (, ) are very small, thus

significant.
We can say that model that used only variable treatment group, height, weight,
and Hospital category is the best model.
People in placebo group have risk 1.5 times than people in the gamma interferon
group to have serious infection .
People with height above the average have risk 0.35 times to have serious
infection than people with height under the average.
People with weight above the average have risk 3.02 times to have serious
infection than people with weight under the average.
Hospital in US-other have risk 2.23 times than hospital in US-NIH for having
serious infection.
Hospital in Europe-Amsterdam have risk 2.13 times than hospital in US-NIH for
having serious infection.
Hospital in Europe-other have risk 4.73 times than hospital in US-NIH for having
serious infection.

Assumptions Test

Metode Log-Log Survival

Goodness of Fit
Ho : Cox PH Assumption is valid (The Model is fit)
Ha : Cox PH Assumption is not valid

Time Dependent Covariate

Ho : Cox PH Assumption is valid (The Model is fit)
Ha : Cox PH Assumption is not valid

Goodness of Fit (Use Strata)

Ho : Cox PH Assumption is valid (The Model is fit)
Ha : Cox PH Assumption is not valid

Time Dependent Covariate (Use Strata)

Ho : Cox PH Assumption is valid (The Model is fit)
Ha : Cox PH Assumption is not valid

Cox PH Model with Stratification

Interpretation
If we use 5% significant level, variable that reject null hypothesis are weight
and hospital category.
But if we used 10% level of significant, all the variables in best model are reject
null hypothesis, which mean variable treatment group, weight and hospital
category have effect for the occurrence of serious infection (if we used variable
height as Strata.
People in placebo group have risk 1.49 times than people in the gamma
interferon group to have serious infection .
People with weight above the average have risk 3.06 times to have serious
infection than people with weight under the average.
Hospital in US-other have risk 2.33 times than hospital in US-NIH for having
serious infection.
Hospital in Europe-Amsterdam have risk 2.12 times than hospital in US-NIH for
having serious infection.
Hospital in Europe-other have risk 4.83 times than hospital in US-NIH for having
serious infection.

Thank You